Six new 9,19-cycloartane triterpene derivatives,as well as 3 known analogues(7–9),were isolated from the roots of Cimicifuga foetida L.Their structures were established on the basis of extensive spectroscopic analyse...Six new 9,19-cycloartane triterpene derivatives,as well as 3 known analogues(7–9),were isolated from the roots of Cimicifuga foetida L.Their structures were established on the basis of extensive spectroscopic analyses(IR,UV,ORD,HRESIMS,1D and 2D NMR).展开更多
AIM: To study the 9, 19-cycloartane triterpenes from the roots of Cimicifuga foetida. METHOD: Chromatographic separations by silica gel, C18 reversed phase silica gel, and high-performance liquid chromatography(HPLC) ...AIM: To study the 9, 19-cycloartane triterpenes from the roots of Cimicifuga foetida. METHOD: Chromatographic separations by silica gel, C18 reversed phase silica gel, and high-performance liquid chromatography(HPLC) were used. All of the structures were elucidated on the basis of spectroscopic analysis and chemical methods. RESULTS: Five 9, 19-cycloartane triterpenes,(3β, 12β, 15α, 24R)-12, 2'-diacetoxy-24, 25-epoxy-15-hydroxy-16, 23-dione-3-O-α-L-arabinopyranoside(1), actein(2), 23-epi-26-deoxyactein(3), asiaticoside B(4), and 12β-hydroxycimigenol(5) were isolated from the roots of Cimicifuga foetida. CONCLUSION: Compound 1 is a new triterpene with two acetoxy groups at C-2' and C-12.展开更多
目的:分析新型冠状病毒感染(COVID-19)相关心律失常的文献,探索该领域的研究现状、热点并预测未来的趋势,为后来的研究者提供借鉴。方法:选择Web of Science的核心合集数据库,每项研究都进行了文献计量和视觉分析,使用CiteSpace和VOSvie...目的:分析新型冠状病毒感染(COVID-19)相关心律失常的文献,探索该领域的研究现状、热点并预测未来的趋势,为后来的研究者提供借鉴。方法:选择Web of Science的核心合集数据库,每项研究都进行了文献计量和视觉分析,使用CiteSpace和VOSviewer软件生成知识图谱。结果:共鉴定出768篇文章,发文涉及美国、意大利和中国为首的319个国家/地区和4 366个机构,领先的研究机构是梅奥诊所和哈佛医学院。New England Journal of Medicine是该领域最常被引用的期刊。在6 687位作者中,Arbelo Elena撰写的研究最多,Guo T被共同引用的次数最多,心房纤颤是最常见的关键词。结论:随着COVID-19的暴发,对COVID-19所致新发/进行性心律失常事件的研究蓬勃发展,未来的研究者可能会对COVID-19感染后新发或遗留的快速性心律失常/缓慢性心律失常的发生机制进行进一步的探索。展开更多
目的:探讨急性期基因背景不明的轻型非心源性脑梗死患者行替格瑞洛或氯吡格雷抗血小板治疗的价值,为临床更高效、精准治疗提供参考。方法:选取新疆生产建设兵团第六师医院2022年1月至2023年6月收治的150例基因不明的急性轻型非心源性脑...目的:探讨急性期基因背景不明的轻型非心源性脑梗死患者行替格瑞洛或氯吡格雷抗血小板治疗的价值,为临床更高效、精准治疗提供参考。方法:选取新疆生产建设兵团第六师医院2022年1月至2023年6月收治的150例基因不明的急性轻型非心源性脑梗死患者为研究对象,充分向患者及(或)其家属说明各治疗方案下,采用随机数字表法分为A组、B组与C组,观察与比较每组患者美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、Barthel指数量表(Barthel index,BI)评分变化情况,并统计患者不良反应发生情况与复发率。结果:三组治疗21d、90d后的NIHSS、BI评分对比差异无统计学意义(P>0.05)。治疗90d后随访,三组出血发生率、消化道不良反应发生率对比差异无统计学意义(P>0.05);A组、C组脑梗死复发率(2.00%、4.00%)相当(P>0.05),但均低于B组(P<0.05)。结论:替格瑞洛联合阿司匹林双抗方案可绕行CYP2C19基因缺陷,在治疗急性轻型非心源性脑梗死中,与传统氯吡格雷双抗对改善患者神经与日常生活功能效果相当,但能更有效地预防90d内脑梗死复发,在基因背景不明下,疗效更具优势。展开更多
基金This project was supported by Program for National Natural Science Foundation of China(Nos.U1132604 and 81302670)The Major Deployment Program of the CAS(No.KSZDEW-Z-004-03)Foundation of State Key Laboratory of Phytochemistry and Plant Resources in West China(P2008-ZZ05).
文摘Six new 9,19-cycloartane triterpene derivatives,as well as 3 known analogues(7–9),were isolated from the roots of Cimicifuga foetida L.Their structures were established on the basis of extensive spectroscopic analyses(IR,UV,ORD,HRESIMS,1D and 2D NMR).
基金supported by the National Natural Science Foundation of China(No.U1132604)Knowledge Innovation Program of the CAS(No.KZCX2-XB2-15-03)Foundation of State Key Laboratory of Phytochemistry and Plant Resources in West China(P2008-ZZ05)
文摘AIM: To study the 9, 19-cycloartane triterpenes from the roots of Cimicifuga foetida. METHOD: Chromatographic separations by silica gel, C18 reversed phase silica gel, and high-performance liquid chromatography(HPLC) were used. All of the structures were elucidated on the basis of spectroscopic analysis and chemical methods. RESULTS: Five 9, 19-cycloartane triterpenes,(3β, 12β, 15α, 24R)-12, 2'-diacetoxy-24, 25-epoxy-15-hydroxy-16, 23-dione-3-O-α-L-arabinopyranoside(1), actein(2), 23-epi-26-deoxyactein(3), asiaticoside B(4), and 12β-hydroxycimigenol(5) were isolated from the roots of Cimicifuga foetida. CONCLUSION: Compound 1 is a new triterpene with two acetoxy groups at C-2' and C-12.
文摘目的:分析新型冠状病毒感染(COVID-19)相关心律失常的文献,探索该领域的研究现状、热点并预测未来的趋势,为后来的研究者提供借鉴。方法:选择Web of Science的核心合集数据库,每项研究都进行了文献计量和视觉分析,使用CiteSpace和VOSviewer软件生成知识图谱。结果:共鉴定出768篇文章,发文涉及美国、意大利和中国为首的319个国家/地区和4 366个机构,领先的研究机构是梅奥诊所和哈佛医学院。New England Journal of Medicine是该领域最常被引用的期刊。在6 687位作者中,Arbelo Elena撰写的研究最多,Guo T被共同引用的次数最多,心房纤颤是最常见的关键词。结论:随着COVID-19的暴发,对COVID-19所致新发/进行性心律失常事件的研究蓬勃发展,未来的研究者可能会对COVID-19感染后新发或遗留的快速性心律失常/缓慢性心律失常的发生机制进行进一步的探索。
文摘目的:探讨急性期基因背景不明的轻型非心源性脑梗死患者行替格瑞洛或氯吡格雷抗血小板治疗的价值,为临床更高效、精准治疗提供参考。方法:选取新疆生产建设兵团第六师医院2022年1月至2023年6月收治的150例基因不明的急性轻型非心源性脑梗死患者为研究对象,充分向患者及(或)其家属说明各治疗方案下,采用随机数字表法分为A组、B组与C组,观察与比较每组患者美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、Barthel指数量表(Barthel index,BI)评分变化情况,并统计患者不良反应发生情况与复发率。结果:三组治疗21d、90d后的NIHSS、BI评分对比差异无统计学意义(P>0.05)。治疗90d后随访,三组出血发生率、消化道不良反应发生率对比差异无统计学意义(P>0.05);A组、C组脑梗死复发率(2.00%、4.00%)相当(P>0.05),但均低于B组(P<0.05)。结论:替格瑞洛联合阿司匹林双抗方案可绕行CYP2C19基因缺陷,在治疗急性轻型非心源性脑梗死中,与传统氯吡格雷双抗对改善患者神经与日常生活功能效果相当,但能更有效地预防90d内脑梗死复发,在基因背景不明下,疗效更具优势。